The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells

Prostate

Volumn 29, Issue 3, 1996, Pages 177-182

  Walls, Ronald ^a   Thibault, Alain ^a,c   Liu, Lei ^a,c   Wood, Chris ^b   Kozlowski, James M ^b   Figg, William D ^a   Sampson, Maureen L ^a   Elin, Ronald J ^a   Samid, Dvorit ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

aromatic fatty acid; differentiation therapy; tumor markers

Indexed keywords

BUTYRIC ACID; CALCITRIOL; FATTY ACID; PHENYLACETIC ACID; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID; SURAMIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; CARCINOMA; CELL DIFFERENTIATION; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; PHENYLACETATES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RATS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0029800207     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199609)29:3<177::AID-PROS3>3.0.CO;2-B     Document Type: Article

References (22)

1. Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE: Prostate specific antigen in hormonally-treated stage D2 prostate cancer: Is it always an accurate indicator of disease status? J Urol 145:802-806, 1991.
2. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141:1076-1083, 1989.
3. Nadji M, Tabei SZ, Castro A, Chu TM, Murphy GP, Wang MC, Morales AR: Prostate specific antigen: An immunohistologic marker for prostatic neoplasms. Cancer 48:1229-1232, 1981.
4. Ahmann FR, Schifman RB: Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostate cancer. J Urol 137:431-434, 1987.
5. Stamey TA, Kabalin JN: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 141:1070-1075, 1989.
6. Oesterling JE, Chaun DW, Epstein JI, Kimball AW, Bruzek DJ, Rock RC, Brendler CB, Walsh PC: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 139:766-772, 1988.
7. Cadeddu JA, Pearson JD, Partin AW, Epstein JI, Carter BH: Relationship between changes in prostate specific antigen and prognosis of prostate cancer. Urology 42: 383-389, 1993.
8. Dupont A, Leonello C, Gomez JL, Thibeault MM, Tremblay M, Labrie F: Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J Urol 146:1064-1068, 1991.
9. Ercole CJ, Langr PH, Mathisen M, Chiou RK, Reddy PK, Vessella, RL: Prostate specific antigen and acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 138:1181-1184, 1987.
10. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142:1011-1017, 1989.
11. Fossa SD, Paus E: Reduction of serum prostate specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. A preliminary report. Eur J Urol 26:29-34, 1994.
12. Scher HI, Curley T, Yeh S, Iversen JM, O'Dell M, Larson SM: Therapeutic alternatives for hormone-refractory prostatic cancer. Semin Urol 10:55-64, 1992.
13. Samid D, Shack S, Sherman LT: Phenylacetate: A novel nontoxic inducer of tumor cell differentiation. Cancer Res 52:1988-1992, 1992.
14. Samid D, Shack S, Myers CE: Selective growth arrest and maturation of prostate cancer cells in vitro by nontoxic, pharmacological concentrations of phenylacetate. J Clin Invest 91:2288-2295, 1993.
15. Svanholm H: Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase. Acta Path Microbiol Immunol Scand A 94:7, 1986.
16. Ellis DW, Leffers S, Davies JS, Ng ABP: Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Amer. J Clin Pathol 81:279-284, 1984.
17. Stein BS, Vangore S, Peterson RO, Kendall AR: Immunoperoxidase localization of prostate specific antigen. Am J Surg Pathol 6:553, 1982.
18. Thibault A, Cooper MR, Figg WD, Venzon DJ, Tompkins AC, Weinberger MB, Headlee D, Sartor AO, McCall N, Samid D, Myers CE: A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54:1690-1694, 1994.
19. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE: Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75:2932-2938, 1995.
20. Young Y-FC, Montgomery TB, Andrews EP, Qiu S, Bilhartz LD, Tindall JD: Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51: 3748-3752, 1991.
21. Stamey TA, Ekman PE, Blakenstein MA, Copper EH: Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Scand J Urol Nephrol (suppl) 162:73-87, 1994.
22. Cunha GR, Donjancour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimua Y: The endocrinology and developmental biology of the prostate. Endocr Rev 8:338-362, 1987.